• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Novartis Doesn't Appear Ready to Make Healthy Move Higher

The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.
By BRUCE KAMICH
Jun 29, 2018 | 09:25 AM EDT
Stocks quotes in this article: NVS

Following some corporate announcements, Novartis AG (NVS) is trading higher in pre-market action Friday. Let's check the charts and indicators of this drugmaker to see if this will generate a sustained reversal to the upside.

In this daily bar chart of NVS, below, we can see that the price of NVS has suffered since the end of January. Prices are below the declining 50-day simple moving average line as well as the bearish 200-day average line. The daily On-Balance-Volume (OBV) line did not peak and turn lower until April, but its decline tells us that sellers have been more aggressive. On the positive side, the 12-day price momentum indicator shows a bullish divergence from February. The momentum indicator makes higher lows from February to May to June while prices make lower lows. This divergence tells us that the pace of the decline slowed from February. A slowing decline happens when buyers come in on a scale-down. A bullish divergence can foreshadow a rally or reversal.

In this weekly bar chart of NVS, below, we have mixed signals. NVS has been trading below the declining 40-week moving average line for several months, but prices are down in a potential support area from late 2016. The weekly OBV line has been in a decline from the beginning of 2018, but the pattern over the past three years is not positive. In the lower panel is the 12-week price momentum study, which shows that downside momentum has slowed -- a positive.

In this Point and Figure chart of NVS, below, we can see (left scale) that there is good support or at least volume from $72 down to $66. On the upside, the chart does not really improve until prices rally back to $84.

Bottom line: NVS probably will make a move to the upside today and we may have made a low, but we are a long way from a bottom and a sustained move higher. A close above $76 will break the bearish 50-day moving average line, and that will be a start in the right direction.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | How-to | Risk Management | Stocks

More from Healthcare

I'm Buying Arcturus Therapeutics Stock and Here's the Reason Why

Jim Collins
Apr 5, 2021 10:15 AM EDT

My COVID vaccine eligibility actually began about a week before my symptoms began.

Gilead Sciences Quant Upgrade Got Me Thinking

Bruce Kamich
Mar 31, 2021 1:55 PM EDT

The upgrade got my attention, but positive-looking charts pushed me over the edge.

Jim Cramer: For This Pandemic, and the Next, There Are Several Stocks I Like Now

Jim Cramer
Mar 31, 2021 7:01 AM EDT

There's an undercurrent that will grow over time, basically what tailwinds from the pandemic will stay with us after the pandemic's over.

The Doctor Found Something Amiss on the Charts of Teladoc

Bruce Kamich
Mar 30, 2021 2:27 PM EDT

The name appears bearish and risky right now.

Here's Why I'm Avoiding AstraZeneca Stock

Jim Collins
Mar 25, 2021 10:00 AM EDT

The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:44 PM EDT PAUL PRICE

    Pretty Incredible + Hard to Believe

  • 11:18 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 5 Pillars of Exceptional Trading
  • 08:05 AM EDT BOB LANG

    Bitcoin vs. Gold: Which Should You Invest In Now?

    Read my article TheStreet here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login